Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis
β Scribed by Po-lin Tseng; Sheng-Nan Lu; Hung-Da Tung; Jing-Houng Wang; Chi-Sin Changchien; Chuan-Mo Lee
- Book ID
- 108885771
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 80 KB
- Volume
- 12
- Category
- Article
- ISSN
- 1352-0504
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Famciclovir (FCV) and lamivudine (LAM) reduce viral replication in patients with recurrent hepatitis B virus (HBV) infection after orthotopic liver transplantation (OLT). Eighteen of 20 patients with insufficient response to FCV were treated with 100 mg LAM daily after OLT. These patients had s
Three-hundred forty-one HBsAg-positive family members of 152 patients with chronic hepatitis B virus infection (47 asymptomatic carriers, 59 with chronic hepatitis, 17 with cirrhosis and 29 with hepatocellular carcinoma) were prospectively studied to determine the morbidity and mortality from chroni